Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis

H Li1, Y Zhang2, A Ströse3, D Tedesco4, K Gurova3 and G Selivanova*1

The malfunction of the p53 tumor suppressor pathway is required for the development of most cancers. The restoration of p53 in vivo exerts an efficient suppression of different types of established tumors, supporting the idea of pharmacological restoration of p53 to combat cancer. A set of p53-reactivating compounds, including PRIMA-1MET/Apr-246, nutlin, RITA, MI compounds, tenovins and others, have been identified and some of them are currently being tested in clinical trials. However, the consequences of p53 activation vary, ranging from cell death to cell survival, and are difficult to predict. As the induction of apoptosis, but not growth arrest, is the preferable outcome of pharmacological activation of p53, it is imperative to understand the mechanism of p53-mediated cell fate decisions for the efficient clinical application of p53-targeting drugs.

It is well established that the induction of pro-apoptotic genes (that is, Puma, Noxa etc) is required for the initiation of apoptosis by p53. However, p53 activated by the MDM2 inhibitor nutlin, in spite of the induction of pro-apoptotic Puma and Noxa, induces cell cycle arrest in a number of cancer lines, with no signs of apoptosis. Hence, the induction of pro-apoptotic genes by p53 is necessary, but not sufficient to induce efficient cell death. Several other mechanisms have been reported to contribute to p53-mediated apoptosis, including the inhibition of survival factors, the repression of pro-survival pathways, such as Akt-PI3K and IGFR, and the inhibition of glycolytic enzymes. But how p53 orchestrates these distinct sets of genes to induce apoptosis remains unclear. Our previous analysis of genome-wide chromatin occupancy by p53 revealed a similar binding pattern of p53 upon nutlin, RITA and 5-fluorouracil (5-FU) treatment, regardless of the differences in transcriptional program and biological outcome. This finding implies the importance of cofactors in p53-mediated cell fate decisions. For example, Sp1, a ubiquitous transcription factor (TF), has been shown to cooperate with p53.

Recent development of the genome-wide loss-of-function screen using pooled siRNA or short hairpin RNA (shRNA) libraries facilitates the understanding of p53-mediated cell cycle arrest. In the present study, using genome-wide shRNA screen integrated with transcriptomic and chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) analysis, we addressed the mechanisms of p53-induced apoptosis in human cancer cells and identified Sp1 as one of its essential determinants.

Results

Genome-wide shRNA screen indicates Sp1 as a central modulator of p53-mediated apoptosis. We tested the biological effect of five well-studied p53-activating chemical compounds, nutlin, RITA, actinomycin D (ActD), cisplatin (CDDP) and 5-FU, in three wild-type p53-expressing human cancer cell lines of different origin, including MCF-7 breast cancer cell lines, with no signs of apoptosis. Hence, the induction of pro-apoptotic genes by p53 is necessary, but not sufficient to induce efficient cell death. Several other mechanisms have been reported to contribute to p53-mediated apoptosis, including the inhibition of survival factors, the repression of pro-survival pathways, such as Akt-PI3K and IGFR, and the inhibition of glycolytic enzymes. But how p53 orchestrates these distinct sets of genes to induce apoptosis remains unclear. Our previous analysis of genome-wide chromatin occupancy by p53 revealed a similar binding pattern of p53 upon nutlin, RITA and 5-fluorouracil (5-FU) treatment, regardless of the differences in transcriptional program and biological outcome. This finding implies the importance of cofactors in p53-mediated cell fate decisions. For example, Sp1, a ubiquitous transcription factor (TF), has been shown to cooperate with p53.

Recent development of the genome-wide loss-of-function screen using pooled siRNA or short hairpin RNA (shRNA) libraries facilitates the understanding of p53-mediated cell cycle arrest. In the present study, using genome-wide shRNA screen integrated with transcriptomic and chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) analysis, we addressed the mechanisms of p53-induced apoptosis in human cancer cells and identified Sp1 as one of its essential determinants.

The malfunction of the p53 tumor suppressor pathway is required for the development of most cancers. Reinstate-ment of p53 in vivo exerts an efficient suppression of different types of established tumors, supporting the idea of pharmacological restoration of p53 to combat cancer. A set of p53-reactivating compounds, including PRIMA-1MET/Apr-246, nutlin, RITA, MI compounds, tenovins and others, have been identified and some of them are currently being tested in clinical trials. However, the consequences of p53 activation vary, ranging from cell death to cell survival, and are difficult to predict. As the induction of apoptosis, but not growth arrest, is the preferable outcome of pharmacological activation of p53, it is imperative to understand the mechanism of p53-mediated cell fate decisions for the efficient clinical application of p53-targeting drugs.

It is well established that the induction of pro-apoptotic genes (that is, Puma, Noxa etc) is required for the initiation of apoptosis by p53. However, p53 activated by the MDM2 inhibitor nutlin, in spite of the induction of pro-apoptotic Puma and Noxa, induces cell cycle arrest in a number of cancer lines, with no signs of apoptosis. Hence, the induction of pro-apoptotic genes by p53 is necessary, but not sufficient to induce efficient cell death. Several other mechanisms have been reported to contribute to p53-mediated apoptosis, including the inhibition of survival factors, the repression of pro-survival pathways, such as Akt-PI3K and IGFR, and the inhibition of glycolytic enzymes. But how p53 orchestrates these distinct sets of genes to induce apoptosis remains unclear. Our previous analysis of genome-wide chromatin occupancy by p53 revealed a similar binding pattern of p53 upon nutlin, RITA and 5-fluorouracil (5-FU) treatment, regardless of the differences in transcriptional program and biological outcome. This finding implies the importance of cofactors in p53-mediated cell fate decisions. For example, Sp1, a ubiquitous transcription factor (TF), has been shown to cooperate with p53.

Recent development of the genome-wide loss-of-function screen using pooled siRNA or short hairpin RNA (shRNA) libraries facilitates the understanding of p53-mediated cell cycle arrest. In the present study, using genome-wide shRNA screen integrated with transcriptomic and chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) analysis, we addressed the mechanisms of p53-induced apoptosis in human cancer cells and identified Sp1 as one of its essential determinants.
carcinoma cells, SJSA osteosarcoma cells and HCT116 colorectal cancer cells, and an isogenic derivative of HCT116 cells with p53 deletion (HCT116 TP53−/− cells), as shown in Supplementary Figures S1A and B. In MCF-7 and HCT116 cells, RITA induced apoptosis (Figures 1a and b), with no signs of cell cycle arrest (Figure 1c), p53-dependence of apoptosis was confirmed by using HCT116 TP53−/− cells (Figure 1a). Furthermore, p53-mediated apoptosis induced by RITA was transcription-dependent, because it was totally halted by pifithrin (PFT)-α, a chemical inhibitor of the p53 transcriptional activity,16 but not affected by PFT-μ, which inhibits p53 binding to mitochondria by reducing its affinity to anti-apoptotic proteins Bcl-XL and Bcl-2 but has no effect on p53-dependent transactivation19 (Figure 1b). Therefore, we have chosen MCF-7 and HCT116 cells treated with RITA to investigate the cofactors needed for p53-mediated apoptosis. Nutlin, which predominantly induced cell cycle arrest in MCF-7 and HCT116 cells, was selected for comparison.

Next, we performed genome-wide shRNA screen in MCF-7 cells treated with RITA using a pool of lentiviral shRNA constructs, composed of 27,290 shRNAs targeting 5046 known human genes (Figure 1d, see Supplementary Information Methods for details). By deep sequencing, we obtained 20 million individual measurements of the abundance of shRNAs after treatment with RITA, which reflect the effect of shRNA on apoptosis induced by RITA (Supplementary Table S1). We identified 8753 shRNAs whose abundance was significantly different in control (DMSO) and RITA-treated cells based on following criteria: (i) P-value < 0.1, (ii) FDR < 0.3 and (iii) P-values of the weighted Z-scores, P(wZ) < 0.1, which integrate the information from multiple shRNAs targeting a single gene, thus minimizing the impact of possible off-target effects. Fifteen out of these genes were selected for validation. We created cell lines stably expressing independent shRNAs (obtained from Sigma, St. Louis, MO, USA) against these genes and determined their viability after RITA treatment relative to a control cell line expressing a nontargeting shRNA (Supplementary Table S2). Validation studies showed that the depletion of 9 of 15 candidate genes changed cell viability on RITA treatment (Supplementary Table S2). Thus, our screening approach successfully identified new genes that modulate apoptosis induced by p53. To decrease the false positives, we selected a more stringent cutoff based on criteria (i) P-value < 0.05, (ii) FDR < 0.1 and (iii) P(wZ) < 0.1 for further analysis and identified 520 shRNAs. Hierarchical clustering analysis demonstrated the efficient clustering of the biological replicates of control and RITA-treated cells and revealed two groups of genes: synthetic lethal nodes (SLNs), depletion of which sensitized cells to RITA treatment (the ratio of read counts between DMSO and RITA > 1), and resistance nodes (RNs), depletion of which rendered cells resistant to RITA treatment (the ratio of read counts between DMSO and RITA < 1). Our screen for factors modulating p53-induced apoptosis revealed much less RNs than SLNs (40 RNs, 0.8% of total number of genes tested versus 445 SLNs, 8.03% of total number of genes) (Figure 1e). This observation is different from previous genome-wide shRNA screen8 studying p53-mediated cell cycle arrest, which identified a similar number of SLNs and RNs (Supplementary Figure S2).

First, we focused our efforts on the RNs, whose depletion results in bypass of p53-mediated apoptosis. We did not identify pro-apoptotic genes (selected according to KEGG: hsa04210) among RNs (Supplementary Table S3). This suggests that the depletion of a single pro-apoptotic gene has little effect on p53-mediated apoptosis. Pathway analysis using DAVID tool could not identify any known pathway overrepresented among RNs. Therefore, we performed the analysis of functional connections between proteins encoded by RNs using STRING software. Twenty-two out of 40 RNs had at least two connections, as shown in Figure 1f. Notably, these 22 RNs were all directly or indirectly connected with Sp1. Among them, nine genes have been identified as direct transcriptional targets of Sp1, including AKR1C1, TBXAS1, SULT1A1, HDP, SCAP, Sp3, FCER1A, CITED2 and Sp1 itself (Supplementary Table S4). In addition, TAF1-mediated histone acetylation has been shown to be required for the binding of Sp1 to cyclin D1 promoter.20 Similar analysis performed with all SLNs and RNs resulted in p53 being at the center of the network together with several TFs including Sp1, AP1, SAMD2 and RXRA (Supplementary Figure S3). Among these TFs, only Sp1 was identified as RN by genome-wide shRNA screen (Supplementary Table S3). Thus, our analysis indicates that Sp1 may serve as a crucial modulator of p53-mediated apoptosis.

**Sp1 is a key determinant of p53-mediated apoptosis but is not required for p53-mediated cell cycle arrest.** Next, we addressed the effects of Sp1 on p53-induced apoptosis. Sp1 depletion resulted in a greater than 50% reduction of the apoptosis induced by RITA (Figure 2a), which was also evident in a long-term viability assay (Supplementary Figures S4A and B). Furthermore, p53-induced apoptosis upon CDDP or 5-FU treatment was rescued by Sp1 depletion as well, which excluded the possibility of a compound-specific effect (Figure 2a). Nutlin and ActD, which induced p53-mediated cell cycle arrest in MCF-7 cells, did not initiate apoptosis after Sp1 depletion (Figure 2a). However, Sp1 overexpression converted growth arrest into robust apoptosis in nutlin-treated MCF-7 and HCT116 cells (Figure 2b, Supplementary Figure S4C). This outcome was p53 dependent, as no apoptosis was induced by nutlin in p53-null cells on Sp1 overexpression (Figure 2b, Supplementary Figure S4C).

Considering the previously reported role of Sp1 in cell cycle control,21 we examined the effect of Sp1 depletion on cell cycle in MCF-7 and HCT116 cells treated with RITA or nutlin. Although Sp1 depletion itself slightly increased G1 population in MCF-7, it did not change the cell cycle distribution upon RITA treatment (Figure 2c). In line with these data, an equivalent level of cell cycle arrest was induced by nutlin in Sp1-depleted and -nondepleted cells (Figure 2d), suggesting that Sp1 is not required for p53 to induce cell cycle arrest.

**Integrated analysis suggests Sp1 involvement in p53-mediated transcriptional repression.** As the apoptosis induced by p53 activation is transcription-dependent in our system, we performed the genome-wide analysis of gene expression profiles to investigate the effect of Sp1 on p53-mediated transcriptional program. Sp1 depletion significantly affected the p53 transcriptional response induced by
RITA (Figure 3a and Supplementary Figure S5): 57.53% of induced genes and 41.91% of repressed genes were not differentially expressed in the absence of Sp1. Moreover, 37.31% of induced genes were repressed and 48.42% of repressed genes were induced in RITA-treated cells on Sp1 depletion (Figure 3b). Interestingly, the induction upon RITA treatment of some well-known p53 pro-apoptotic targets such as Noxa, PUMA, Fas, and TNFRSF10A and TNFRSF10B was not reversed by Sp1 depletion (Figure 3a). Our combined analysis of shRNA screen data and microarray data showed that, when taken individually, none of these pro-apoptotic genes was absolutely required for the induction of apoptosis (Supplementary Figure S6). Actually, the expression of these pro-apoptotic p53 targets was activated both by RITA (triggering apoptosis) and nutlin (inducing cell cycle arrest) (Figure 3a), although the expression profile induced by p53 on RITA treatment was quite different from that induced by nutlin, regardless of Sp1 status (Supplementary Figures S7A and B). These results provided further evidence for the minor role of these pro-apoptotic genes in the rescue of cells from p53-induced apoptosis on Sp1 depletion.

In addition, genes important for cell cycle arrest, GADD45a, CDKN1A, SESN1 and BTG2, were also induced by both nutlin and RITA. Moreover, the expression of these genes was still activated by RITA in Sp1-depleted cells (Supplementary Figure S7C). Thus, the induction of this set of growth arrest genes was not sufficient to induce cell cycle arrest upon RITA treatment, most probably due to the MDM2-mediated degradation of p21 and hnRNP K, as we have reported.22
Although we did not find a pathway enriched within RNs (Figure 3c), there were 18 pathways enriched within SLNs (Supplementary Figure S8). This implies that the inhibition of certain genes from these pathways will be synthetic lethal with RITA. Besides ‘cell cycle’ and ‘apoptosis’, there are several pathways also related to apoptosis, such as ‘Wnt signaling’, ‘TGFb signaling’, ‘MAPK signaling’, ‘Cell adhesion’ and pathways involved in metabolism.11,23–26

Pathway analysis of the microarray data revealed that 6 of these 18 synthetic lethal pathways were uniquely enriched with p53-downregulated genes upon RITA treatment, but not with p53-upregulated genes or genes altered by nutlin (Figure 3c). These data indicate the importance of p53-mediated transcriptional repression of genes involved in six pathways for the induction of apoptosis. Importantly, these six pathways were regulated in a Sp1-dependent manner, as evidenced from the analysis of microarray data in Sp1-depleted cells (Figure 3c).

In our previous study, we have demonstrated that the transcriptional repression of survival genes by p53 is required for robust apoptosis, but we have not identified cofactors required for it.8 Our results presented above suggest Sp1 as an important cofactor conferring the pro-apoptotic transcriptional repression by p53.

Sp1 cooperation at p53 target genes is required for the p53-mediated pro-apoptotic transcriptional repression.

To address the mechanism of co-regulation of repressed genes by p53 and Sp1, we analyzed the p53 genome occupancy on the 1078 genes, which were co-repressed by p53 and Sp1 upon RITA but not nutlin treatment (Figure 4a), using the p53 ChIP-seq data previously reported by us.12 Among these genes, 227 genes were bound by p53 after RITA treatment (Figure 4b) and were enriched in 10 pathways (Supplementary Figure S9). Thus, these genes and pathways are under the direct transcriptional control of p53. Three out of these 10 pathways, ‘apoptosis’, ‘Wnt signaling pathway’ and ‘TGF-beta signaling pathway’, were identified as being synthetic lethal with p53-mediated apoptosis (compare Figures 3c and 4d). The other 851 genes...
that were not bound by p53 are most likely repressed in an indirect way. Among the 227 p53-bound genes, 173 genes were also bound by p53 after nutlin treatment, leaving 54 unique targets for p53 activated by RITA (Figure 4b).

Using oPOSSUM, we performed motif analysis to find Sp1 response elements (RE) in p53-bound genes. Forty-eight of the 54 'RITA-unique' p53 targets and 162 of the 173 targets 'common for RITA and nutlin' have been found to contain conserved Sp1 RE, thus identifying them as potential common target genes of p53 and Sp1 (Supplementary Tables S5 and S6). Interestingly, further investigation of ChIP-seq data showed that around 71% of these potential common targets contained p53-binding sites in the vicinity (±500 bp) of the putative Sp1 RE (Figure 4c). Analysis of functional protein association among these 227 p53 targets produced a network centered by p53 and Sp1 including \(\text{MAPK8}, RARA, \text{SAMD3}, \text{CREBBP}, \text{RUNX1}, \text{BTRC} \) and \(\text{NCOA3}\) (Supplementary Figure S10).

Next, we randomly selected three genes, \(\text{DSP}, \text{KIAA0513}\) and \(\text{LARP1}\), from the 54 'RITA-unique' targets, and three genes, \(\text{MAPK8}, \text{ARNT2}, \text{RARA}\), from the 173 'common for RITA/nutlin' targets. For each gene, we detected the binding levels of p53 and Sp1 by ChIP-PCR, using the same primers. The binding profile of p53 and the location of amplified region are shown in Supplementary Figure S11. Regardless of stimuli, p53 was bound to 'RITA-unique' genes as well as to 'common RITA/nutlin' genes tested (Figure 4e). This is consistent with our previous study showing that the majority of p53-bound sites are similar on RITA and nutlin treatment. In line with the predicted overlap of p53-bound sites and Sp1 RE, the binding of Sp1 to all genes was significantly increased after RITA treatment (Figure 4f), suggesting a recruitment of Sp1 upon p53 activation. Furthermore, the presence of p53 at these genes was significantly reduced in Sp1-depleted cells on RITA treatment (Figure 4e). In contrast, the binding of Sp1 to these genes was not increased after nutlin treatment and became even lower than control at \(\text{RARA}\) first intron (Figure 4f), indicating that p53 activated by nutlin does not recruit Sp1 to its binding sites.

We assayed the expression of selected genes by qPCR. p53 repressed these genes on RITA, but not on nutlin treatment, in spite of being present at these genes in both cases (Figure 4g). p53-mediated repression required Sp1, because the suppression of all genes tested was halted by Sp1 depletion (Figure 4g). These results confirmed the data obtained using microarray analysis.

Notably, on nutlin treatment, ectopic expression of Sp1 promoted the binding of Sp1 to \(\text{MAPK8}, \text{ARNT2}, \text{RAR}, \text{DSP}, \text{KIAA0513}\) and \(\text{LARP1}\) and repressed their transcription (Supplementary Figure S12), indicating that Sp1 overexpression may facilitate apoptosis in nutlin-treated cells via similar mechanism as that used by RITA.

Taken together, our results demonstrate that the binding of Sp1 to p53 target genes is required for the pro-apoptotic transcriptional repression by p53.

**Nutlin induces MDM2-mediated degradation of Sp1.** In line with the different binding of Sp1 to p53-repressed targets in cells treated with RITA and nutlin, we found that the protein level of Sp1 was downregulated by nutlin, but not by RITA in both MCF-7 and HCT116 cells (Figure 5a). The same results were obtained in HCT116 p53-null cells, indicating that the reduction in Sp1 protein level by nutlin was not p53 dependent (Figure 5a).

As the transcription of Sp1 was not affected by nutlin (Figure 5b), we studied the downregulation of Sp1 on posttranscription level. The half-life of the Sp1 protein was decreased by nutlin (Figure 5c). This effect was rescued via pretreatment with a proteasome inhibitor MG132 (Figure 5e), indicating proteasome-dependent degradation of Sp1. Despite the suppression of Sp1 transcription (Figure 5b), the stability of Sp1 protein was increased by RITA treatment.
Figure 4  p53-mediated pro-apoptotic transcriptional repression requires the co-binding of Sp1 to p53 target genes. (a) Heatmap representation of the 1078 genes whose repression by RITA was lost in Sp1-depleted cells. (b) Proportion of p53-bound genes (p53 targets) among these 1078 genes is illustrated via Venn diagram. (c) Heatmap shows p53 occupancy within ±500 bp of the putative Sp1 RE in 227 p53-bound genes. '0' indicates the position of the putative Sp1 RE, rows indicate p53 binding (red: high peaks/binding; white: no peaks/binding). (d) Synthetic lethal pathways enriched with 227 p53-bound genes after RITA treatment. $P<0.05$. (e and f) Binding of p53 (e) and Sp1 (f) to selected genes was assessed by ChIP-PCR. (g) The transcriptional level of selected genes was examined by qPCR. In e, f and g, data are presented as mean ± S.D., n = 3.
As shown by co-immunoprecipitation assay, nutlin, but not RITA, reduced the binding of Sp1 to p53 (Supplementary Figure S13A), which was rescued by Sp1 overexpression (Supplementary Figure S13B), suggesting that the formation of p53/Sp1 complex could be directly affected by the level of Sp1.

Along with the downregulation of Sp1 by nutlin, we detected a marked induction of the MDM2 protein, a key negative regulator of p53, on nutlin treatment in both MCF-7 and HCT116 cells (Figure 5a). We obtained similar results in HCT116 p53-null cells (Figure 5a, right panel), which is consistent with the previous study showing that nutlin can stabilize MDM2 protein in a p53-independent manner.28

It has been shown previously that Sp1 could enhance p53 degradation by MDM2 through formation of a Sp1/p53/MDM2 triple protein complex.13 Given the negative correlation between Sp1 and MDM2 protein levels after nutlin treatment, we hypothesized that, on its release from p53, MDM2 stabilized by nutlin could bind to Sp1 and mediate its degradation. A prediction from this hypothesis is that the inhibition of MDM2 would restore Sp1 level on nutlin treatment.

To address this idea, two strategies were employed. First, we compared the effect of nutlin in mouse embryonic fibroblasts (MEFs) deficient for both MDM2 and p53 with that in wild-type MEFs. In wild-type MEFs, the depletion of p53 by siRNA could not prevent the induction of MDM2 and the downregulation of Sp1 by nutlin (Figure 6a). These data further confirmed that the effects of nutlin on MDM2 and Sp1 proteins were p53 independent. In contrast, in MDM2−/−TP53−/−MEFs, the downregulation of Sp1 by nutlin was compromised, in line with our prediction (Figure 6a). Further, we depleted MDM2 using pooled siRNA in HCT116 TP53−/−cells, which also lead to the rescue of Sp1 level on nutlin treatment (Figure 6b). On the other hand, the overexpression of MDM2 resulted in a decreased level of Sp1 protein in MCF-7 cells, regardless of nutlin treatment, suggesting that the effect of MDM2 on Sp1 is not stimuli dependent (Figure 6c). Finally, consistent with our hypothesis, a co-immunoprecipitation assay revealed an increased level of MDM2 bound to Sp1 after nutlin, but not RITA treatment (Figure 6d). Taken together, our data demonstrate that Sp1 downregulation is mediated by nutlin-stabilized MDM2.

Next, we addressed whether MDM2-mediated repression of Sp1 on nutlin treatment is ubiquitination-dependent using MCF-7, HCT116 and HCT116 TP53−/−cells with MDM2 knockdown. We found that Sp1 ubiquitination was promoted by nutlin in all three cell lines, but not in cells with MDM2 knockdown (Figure 6e). Similarly, we observed the induction of Sp1 ubiquitination by nutlin in HCT116 TP53−/−cells expressing ectopic HA-tagged ubiquitin and the absence of enhanced Sp1 ubiquitination in MDM2-depleted cells (Figure 6f). These results support the notion that nutlin-stabilized MDM2 suppresses Sp1 via ubiquitin-dependent degradation.

Although both nutlin and RITA induced MDM2 mRNA (Supplementary Figure S14), the protein level of MDM2 was increased by nutlin, but not by RITA (Figure 5a), in line with previously published study.29 We believe that this might contribute to the observed stabilization of Sp1 protein by RITA (Figure 5d). Furthermore, Sp1 was not required for the induction of either MDM2 mRNA or protein in cells treated with RITA or nutlin (Figure 6g and Supplementary Figure S14), suggesting that MDM2 is not downstream of Sp1 in the pathway that determines the cell fate upon p53 activation.

**Discussion**

The pleiotropic character of the p53 network makes it hard to predict the consequence of p53 activation. The discovery of the mechanisms governing p53-mediated biological...
outcomes is extremely important for the clinical application of p53-based therapies. Here, utilizing genome-wide shRNA screen in combination with transcriptomic and ChIP-seq analysis, we identified Sp1 as an essential determinant of p53-mediated apoptosis. We suggest the model depicted in Figure 7 showing that, upon activating stimuli, p53 induces pro-apoptotic genes encoding Puma, Noxa, Fas and others. In cells with low level of MDM2, activated p53 mediates pro-apoptotic transcriptional repression via recruitment of Sp1 to its RE in p53 target genes, which together with the induction of pro-apoptotic genes triggers efficient apoptosis. However, in cells with high level of MDM2, SP1 degradation is promoted by MDM2. Without recruitment of Sp1, p53 fails to confer pro-apoptotic transcriptional repression and, although pro-apoptotic genes are induced, efficient apoptosis is not triggered.

Although RITA treatment significantly altered the transcription of around 50% of genes in MCF-7 cells, surprisingly, no particular gene or pathway was found to be absolutely necessary for p53-mediated apoptosis. Therefore, the inactivation of a single p53-induced gene or pathway is unlikely to confer resistance in a clinical setting. In contrast, we observed a cumulative effect of RITA-repressed genes on p53-mediated apoptosis, indicating the importance of p53-mediated transcriptional repression for therapeutic effect.

The major efforts to awaken p53-mediated apoptosis in cancer cells are focused on the prevention of the binding of MDM2 to p53. However, the consequences of MDM2 inhibition vary depending on cell type. Here we show that the protection of p53 cofactor Sp1 from MDM2-mediated degradation is crucial for the efficient induction of apoptosis by
p53. Our study indicates that further elucidation of MDM2 substrates involved in p53 signaling may provide new targets and help to develop more efficient strategies for p53-MDM2-based therapies.

Materials and Methods

Cells, plasmid and transfections. HCT116 and HCT116 TPp53−/− were a gift from B Vogele (John Hopkins University, USA). MDM2 and p53 siRNA was from Santa Cruz (Dallas, TX, USA), and GFP siRNA was from Oligoengine (Seattle, WA, USA); pUC-hSp1 and pUC-empty plasmids were gifts from D. X. (Karolinska Institute, SE). Plasmid transfections and siRNA transfections were performed using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) according to manufacturer’s instructions. All shRNAs, except the library for shRNA screen, were from Sigma, Sp1-depleted cell line was established as previously described.11 All cells were grown in IMDM medium with 10% FBS and Rho123-PI staining as described in Ferlini et al. (BD, Mountain View, CA, USA). Apoptosis was assayed by FACS using Annexin V-PI staining, Sub-G1 population detection using PI staining as described in Enge et al. (BD, Mountain View, CA, USA). Analysis was performed using a FACScan with CellQuest software version 4.0.2 and Rhodamine 123 (Rho123) were from Sigma.

Reagents. RITA was obtained from National Cancer Institute (NCI). Nutlin, 5-FU, ActD, CDDP, PFT-α, PFT-β, cycloheximide, MG132, propidium iodide (PI) and Rhodamine 123 (Rho123) were from Sigma. 5-FU, ActD, CDDP, PFT-a, and Rhodamine 123 (Rho123) were from Sigma.

Growth suppression assays. FACS was performed on BD FACScan. Analysis was performed using a FACSScan with CellQuest software version 4.0.2 (BD, Mountain View, CA, USA). Apoptosis was assayed by FACS using Annexin V-PI staining, Sub-G1 population detection using PI staining as described in Enge et al.12 or Rho123-PI staining as described in Ferlini et al.12 Cell cycle and colony formation assay were described as detected in Enge et al.12

Microarray analysis, ChIP-seq, qPCR and chromatin immuno-precipitation. Expression profiling of MCF-7 cells was performed using Affymetrix (Santa Clara, CA, USA) human genome 219 arrays as previously described.11 ChIP-seq data in MCF-7 cells have been reported in Nikulenkov et al.12 Real-time qPCR and ChIP-PCR were performed as described in Li et al.11 Primer sequences are presented in Supplementary Table S7.

Protein extraction and western blots. Western blots were performed according to procedures described in Zawacka-Pankau et al.11 Following antibodies were used for western blotting: p53 (DO-1, Santa Cruz); MDM2 (2A10), Sp1 (PEP2), HA (sc-7392) and GAPDH (H-12) (all from Santa Cruz Biotechnology); Actin (Sigma). For the ubiquitination assay, 10 mM NEM was added to the lysis buffer.

High-throughput data analysis. Microarray data were analyzed with R (http://www.r-project.org/). Pathway analysis was performed with DAVID (gene-enrichment analysis using EASE score, a modified Fisher exact P-value, as threshold).20 ChIP-seq data were analyzed with a web-based tool, Galaxy.21 Functional protein network analysis was performed with STRING.22 Putative binding sites of Sp1 were predicted using sPOSSUM.33

Genome-wide pooled shRNA screen. Genome-wide pooled shRNA screen was performed in MCF-7 cells treated with RITA using a lentivirus-delivered pool of 27,290 shRNAs targeting 5046 known human genes. The experimental procedure and the data processing are described in Supplementary Information Materials and Methods.

Statistics. The SPSS software package (SPSS for Windows, Release 13.0 for Windows, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data obtained from several experiments are reported as mean ± S.D. Student’s test was used to determine statistical significance. A P-value of < 0.05 was considered significant.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. This study was funded by the Swedish Cancer Society, the Swedish Research Council, Karolinska Institutet, European Commission FP6, Ragnar Söderberg foundation and the RPAF/shRNA/Cellecta project funding from Roswell Park Cancer Institute. The publication reflects only the authors’ views. The European Commission is not liable for any use of information herein. We are deeply indebted to our colleagues who shared valuable reagents with us, and grateful to Dr. Marcela Franco and Carsten Bahr for the technical support and valuable suggestions.

Figure 7 Model depicting the contribution of Sp1 to p53-mediated pro-apoptotic transcriptional repression and apoptosis. See Discussion for details.
15. Gualberto A, Baldwin AS Jr. p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem 1995; 270: 19680–19683.

16. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428: 431–437.

17. Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2: 202–206.

18. Komarova EA, Komarov PG, Kondratov RV, Chistov-Tsaiev K, Coon JS, Chemov MV et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733–1737.

19. Strom E, Sathe S, Komarov PG, Chernov OB, Pavlovska I, Shyshynova I et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2: 474–479.

20. Hilton TL, Li Y, Dunphy EL, Wang EH. TAF1 histone acetyltransferase activity in Sp1 and p53-mediated transcription. J Biol Chem 1998; 273: 1465–1492.

21. Enge M, Bao W, Hedstro¨m E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171–183.

22. Pec´ina-Slaus N. Wnt signal transduction pathway and apoptosis: a review. Cancer Cell Int 2010; 10: e22.

23. Zeng L, Rowland RG, Lele SM, Kyprianou N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 2004; 35: 290–297.

24. Brown L, Benchimol S. The involvement of MAPK signaling pathways in determining the cellular response to p53 activation: cell cycle arrest or apoptosis. J Biol Chem 2006; 281: 3832–3840.

25. Ilic´ D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 1996; 134: 547–560.

26. Wale M, Li YC, Wahl GM. MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13: 83–96.

27. van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pinie L et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2012; 10: 1590–1598.

28. Rinaldi C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs Nutlin-3 and RITA. Cancer Res 2009; 69: 6241–6248.

29. Ferlini C, Scambia G. Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange. Nat Protoc 2007; 2: 3111–3114.

30. Li H, Laishrymkanth T, Garofalo C, Enge M, Spintler C, Anchiri A et al. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011; 10: 3346–3358.

31. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009; 4: 44–57.

32. Blankenberg D, Von Kuster G, Coraco N, Ananda G, Lazarus R, Mangan M et al. Galaxy, a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; Chapter 19: Unit 19.10.1-21.

33. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41(Database issue): D808–D815.

34. Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP et al. pOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res 2005; 33: 3154–3164.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/